Faster TRD Remission: Why Measurement-Based Care Matters

What the Research Says

A new clinical commentary published in Psychiatric Times in April 2026 makes a case that feels deceptively simple: patients with treatment-resistant depression (TRD) reach remission faster when their clinicians measure symptoms consistently, adjust dosing quickly based on those measurements, and address side effects proactively rather than waiting them out.

The piece focuses on what researchers call measurement-based care (MBC)—a structured approach to tracking patient-reported outcomes at every visit using standardized scales, then using that data to make faster, more informed treatment decisions. The argument is not that we need better drugs. It's that we're often using the drugs we already have suboptimally: too slowly, with too much tolerance for side effects, and without enough data to know whether a treatment is actually working.

Treatment-resistant depression is typically defined as a failure to respond adequately to at least two antidepressant trials of appropriate dose and duration. It affects an estimated 30% of people diagnosed with major depression—a population that has historically been underserved, passed from provider to provider, and left cycling through medications for months or years without remission. The stakes for getting treatment optimization right are high, and the Psychiatric Times commentary adds clinical weight to calls for a more systematic approach.

The Three Levers Clinicians Are Being Asked to Pull

The guidance centers on three core practices that, taken together, are intended to compress the time between a patient starting a more efficacious treatment and actually feeling better.

1. Systematic symptom measurement. Rather than relying on clinical impression alone, providers are encouraged to use validated tools—like the PHQ-9 or the Montgomery-Åsberg Depression Rating Scale (MADRS)—at every appointment. These scales create a quantitative record of how a patient is responding over time, making it harder to miss a partial response or rationalize staying with a treatment that isn't working.

2. Faster dose adjustment. Once measurement data shows a patient isn't responding, clinicians are encouraged to act on it quickly—adjusting dose, adding an augmentation strategy, or escalating to a more aggressive intervention—rather than defaulting to a 'wait and see' posture. In TRD especially, prolonged exposure to an ineffective treatment carries real costs: continued suffering, neurobiological changes associated with chronic depression, and erosion of a patient's confidence in the treatment process itself.

3. Proactive side effect management. Side effects are frequently the reason patients discontinue treatments before they have a chance to work. The commentary highlights the importance of anticipating known side effect profiles and addressing them early—both to improve tolerability and to retain patients in treatment long enough to assess efficacy.

Why This Is Particularly Relevant to Ketamine Treatment

For readers evaluating ketamine as a treatment option for TRD, this clinical framework lands in a meaningful place. Ketamine—whether administered as IV infusions, intramuscular injections, or intranasal esketamine (Spravato)—is notable precisely because it works through a fundamentally different mechanism than traditional antidepressants, offering rapid onset of action measured in hours rather than weeks. That speed matters most when it's paired with a clinical infrastructure that actually knows how to use it.

The measurement-based care model described in the Psychiatric Times piece maps directly onto how thoughtful ketamine providers should already be operating. When a patient begins a ketamine infusion series—typically six infusions over two to three weeks—providers who are using standardized symptom scales before and after each infusion have real data to work with. They can identify early responders, flag non-responders before completing the full series, and make evidence-based decisions about booster infusions or maintenance dosing rather than operating on intuition.

This is not how all ketamine providers operate. The field has expanded rapidly, and the clinical rigor varies considerably from clinic to clinic. Some providers use structured intake assessments, validated depression scales at every session, and collaborative follow-up protocols with a patient's existing psychiatrist or therapist. Others function more like spa-adjacent wellness services, offering infusions with minimal psychiatric scaffolding. The commentary from Psychiatric Times reinforces why the former approach produces better outcomes—and gives patients a concrete framework for evaluating the providers they're considering.

The faster-adjustment principle also has implications for ketamine specifically. Because ketamine's antidepressant effects can emerge within 24 hours of a first infusion, providers using measurement-based care are in a position to interpret early signal quickly. A patient who reports meaningful improvement after infusion two may be a candidate for a modified maintenance schedule. One who shows no response after three infusions may need a different route of administration, a different adjunct therapy, or a pivot to esketamine. That kind of adaptive decision-making requires data—and getting the data requires measuring in the first place.

Finally, the emphasis on side effect management is directly applicable. Ketamine's most common acute side effects—dissociation, dizziness, elevated blood pressure, and transient anxiety—are well-characterized and largely manageable with appropriate preparation and monitoring. Clinics that discuss these effects in advance, titrate dosing thoughtfully, and create a comfortable treatment environment are practicing exactly the kind of proactive side effect management the research supports. For patients, this is another quality signal worth asking about before committing to a provider.

The Bigger Picture for TRD Treatment in 2026

The Psychiatric Times commentary arrives at a moment when the TRD treatment landscape is more diverse than it has ever been. Alongside ketamine and esketamine, clinicians now have access to psilocybin-assisted therapy (in a limited number of states), transcranial magnetic stimulation (TMS), and newer augmentation strategies that pair atypical antipsychotics with antidepressants. Each of these carries its own evidence base, side effect profile, cost structure, and access limitations.

What the MBC framework implicitly argues is that the proliferation of options is only useful if the clinical decision-making process can keep up with it. A patient with TRD who has failed two antidepressants and is now being evaluated for a more efficacious treatment deserves a provider who is using objective data to guide those escalation decisions—not one who is defaulting to habit, cost considerations alone, or whatever they happen to have in-network.

For patients doing their own research—which is most of the people who find their way to resources like this one—the practical implication is straightforward: the right question to ask isn't just 'does ketamine work for TRD?' It's 'does my provider know how to use it well?' The evidence that ketamine is effective for many people with TRD is substantial. The evidence that measurement-based care improves outcomes across treatment modalities is also substantial. Putting both together is where the real clinical gain lies.

Read the original commentary at Psychiatric Times.